MMP2 and prostate cancer: The CTX-targeted nanovector selectively increased the transfection efficiency of melittin gene in MMP-2 positive human prostate cancer cell line PC3 and inhibited cell viability without affecting the growth of MMP-2 negative NIH3T3 cell line, suggesting the antitumor selectivity of melittin under CTX-targeted nanomodification.